Generic Name:
Ofatumumab
Project Status:
Complete
Therapeutic Area:
Chronic Lymphocytic Leukemia
Manufacturer:
GlaxoSmithKline Inc.
Brand Name:
Arzerra
Project Line:
Reimbursement Review
Project Number:
PC0038-000
NOC Date:
Details
Strength:
20mg /vial
Tumour Type:
Leukemia
Indications:
Chronic Lymphocytic Leukemia
Funding Request:
In combination with chlorambucil, for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior therapy and are inappropriate for fludarabine-based therapy.
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
GlaxoSmithKline Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
A delay in the receipt of marketing authorization (NOC) from Health Canada has impacted the review timeline. The submitter provided additional economic information, which further impacted the review timeline.
Recommendation Type:
Do not reimburse
Clarification:
A procedural review request was received from GlaxoSmithKline Inc. on February 6, 2015. As per Section 3 of the pCODR Procedural Review Guidelines, this procedural review request was submitted on the basis that pCODR failed to act in accordance with its procedures in conducting the review, as described in the pCODR Procedures, and that pERC failed to apply its deliberative framework in formulating its recommendation, as outlined in the pERC Deliberative Framework. As per Section 6 of the pCODR Procedural Review Guidelines, the procedural review request was reviewed by the President and CEO of CADTH, with advice from the pCODR Advisory Committee (PAC) Chair and Vice-Chair. It was determined on February 20, 2015, that the grounds for a procedural review request did not exist. As such, a Notification to Implement has been issued for February 23, 2015.
Clarification:
A delay in the receipt of marketing authorization (NOC) from Health Canada has impacted the review timeline. The submitter provided additional economic information, which further impacted the review timeline.
Funding Request:
In combination with chlorambucil, for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior therapy and are inappropriate for fludarabine-based therapy.
pERC Meeting:
Final Recommendation Issued: